Facebook
Twitter
LinkedIn
ForwardPatient Management Simulator: Treatment Recommendations for Kidney Cancer with Management of Immunotherapy-Related Toxicities
Many factors can influence treatment selection for patients with renal cell carcinoma (RCC), including histology, stage, prognostic risk factors, and lines of therapy. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer have been updated to reflect advances in the comprehensive care of patients with kidney cancer. It is important for you to be aware of new and emerging options in the management of kidney cancer so you can develop individualized treatment plans for patients and manage toxicities related to immunotherapy.
The goal of this educational activity is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to care for patients with kidney cancer. By working through a series of realistic case scenarios, you will experience how to manage a variety of kidney cancer presentations over time. As you make decisions, you will receive expert corrective mentoring from virtual colleagues to help you recognize optimal decision-making patterns.
Target Audience
This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other relevant health care professionals who care for patients with kidney cancer.
Learning Objectives
Following this activity, participants should be able to:
- Compare and contrast different treatment strategies for managing kidney cancer.
- Develop individualized treatment plans for patients with kidney cancer based on disease stage, histology, treatment history, and risk group.
- Recognize, proactively mitigate, and effectively manage immune-related adverse events in patients with kidney cancer who have received immune checkpoint inhibitors.
- Apply the current recommendations and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the care of patients with kidney cancer.
- Evaluate new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the treatment of patients with kidney cancer.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the care of patients with kidney cancer.
Eric Jonasch, MD – Eric Jonasch, MD is a Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. He also serves as Director of the Von Hippel–Lindau Clinical Center at MD Anderson and Co-Director of the MD Anderson Kidney Cancer Research Program.
Kathryn E. Beckermann, MD, PhD – Kathryn E. Beckermann, MD, PhD is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine at Vanderbilt University Medical Center.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Eric Jonasch, MD
AbbVie, Inc.: Grant/Research Support
AVEO Pharmaceuticals, Inc.: Grant/Research Support; Consulting Fee
Bristol Myers Squibb: Grant/Research Support
Corvus: Grant/Research Support
Eisai Inc.: Consulting Fee
Exelixis Inc.: Consulting Fee
Ipsen: Consulting Fee
Merck & Co., Inc.: Grant/Research Support; Consulting Fee
NiKang: Grant/Research Support; Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
ProFoundBio: Grant/Research Support
Telix: Grant/Research Support; Consulting Fee
Kathryn E. Beckermann, MD, PhD
Adicet: Consulting Fee
Alpine Immune Bioscience: Consulting Fee
Aravive: Consulting Fee
Arcus: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
AVEO Pharmaceuticals, Inc.: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Eisai Inc.: Consulting Fee
Exelixis Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Nimbus: Consulting Fee
Xencor: Consulting Fee
NCCN and Syandus Staff Disclosures
The planner listed below has the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Douglas Seifert, PhD
Merck & Co., Inc.: Consulting Fee
Siemens Healthineers: Consulting Fee
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, this activity has been planned and implemented by the National Comprehensive Cancer Network (NCCN) and Syandus. NCCN is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.5 contact hours.
Pharmacists
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-9999-24-107-H01-P
Continuing pharmacy education credit is reported to the CPE Monitor after you have completed the post-test and evaluation and claimed your credits. Be sure to enter your NAPB e-profile ID and date of birth when prompted in the evaluation. Your credit cannot be reported without this information.
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 19, 2025. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 1.5 Lifelong Learning (Part II) credits.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Surgery Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Physicians claiming ABIM, ABPath, or ABS MOC points: ABIM/ABPath/ABS MOC points are reported to ABIM/ABP/ABS once you have completed the post-test and evaluation and claimed your credits. Be sure to enter your learner/diplomate ID and date of birth when prompted in the evaluation. Your credit cannot be reported without this information.
Price
Method of Participation to Earn Credit
- Participants must review all activity information, including the pre-test, learning objectives, faculty disclosure information, simulation scenario(s), and post-activity evaluation.
- To view the first simulation scenario, launch the simulation from the link provided using a PC, Mac, Tablet, or Phone with a 4G or higher internet connection.
- Interact appropriately to satisfy each objective to unlock the next objective and view the next simulation scenario.
- The simulation will track your progress until all scenario objectives are complete.
- Exit the simulation at any time, and your progress will be saved so you can return to finish at a later time.
- As you complete each scenario (1 minimum, 4 total), you will qualify for increasing levels of CE credit (ranging from 0.25 to 1.5 credits). Click or tap "Credit" to determine your CE credit status.
- Upon successful completion of the evaluation, you can download/print a certificate of credit immediately via the browser.
Fee Information
There is no fee to participate in this activity.
Contact Information
For further information about this activity, contact [email protected]; for technical support for this activity, contact [email protected] or 1-888-321-2520.
Privacy and Confidentiality
NCCN and Syandus respect the privacy and confidentiality of users of this activity. The privacy statement for this activity is available from within the activity and by clicking here.
Copyright Statement
This CE-certified simulation activity is licensed to National Comprehensive Cancer Network (NCCN). Copyright © 2024 Syandus Inc and NCCN. All rights reserved. No part of this simulation activity may be reproduced without written permission from NCCN and Syandus Inc.
Required Hardware/software
Any modern phone or tablet with at least 2GB of RAM (typically 3-4 years old or newer), or a PC/Mac that is 5 years old or newer. A good user experience requires a broadband connection of 4G or better via a modern web browser (Chrome, Firefox, Safari, or Edge; Internet Explorer is not supported).